MIAMI, FL--(Marketwire - Nov 1, 2012) - Progressive Care Inc. (
Under the terms of the agreements, which commenced on September 30, 2012, PharmCo will become each facility's designated provider of pharmaceutical products and services. PharmCo will be responsible for providing approved prescription and non-prescription drugs, intravenous products, respiratory supplies, enteral and parenteral nutritional products and other pharmaceutical supplies and services.
Vernon Watson, Chief Executive Officer of Progressive Care, stated, "This is a tremendous opportunity for our Company to secure our position as a leading provider of pharmacy services to the South Florida area." He continued, "In the past year, we have taken several steps to expand our PharmCo operations and drive heightened awareness of our prescription fulfillment and critical care services. We believe that we have hit a milestone where we are beginning to see the results of our growth initiatives and look forward to additional opportunities to serve the South Florida market and beyond."
About Progressive Care, Inc.
Progressive Care, Inc. (RXMD) and its subsidiary, PharmCo, LLC, a provider of prescription pharmaceuticals, specializes in anti-retroviral patient care, long term care and durable medical equipment. Our operations are currently focused on the South Florida market, where management believes demographics are synergistic with its marketing efforts of anti-retroviral patient management and its DME product line. Progressive Care is devoted to improving the quality of life of special needs patients through increasing access to vital medication and equipment, raising awareness, and providing education and other services to local communities and long term care institutions. For more information regarding RXMD, please visit http://www.progressivecareus.com, or view our reports and filings with the Securities and Exchange Commission on http://www.sec.gov.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, including future growth and earnings opportunities of the Company. Actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the Company's ability to retain and to promptly satisfy current backorders and other economic, competitive, governmental, technological, regulatory, manufacturing and marketing risks associated with the Company's business and financial plans. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in the Company's most recent filings with the Securities and Exchange Commission.